Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Archives of Pathology & Laboratory Medicine

• Publication date

  2018-01-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.5858/arpa.2017-0388-CPPMID 29355391
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  2018cited by this paper
• ERBB2‐Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies

  2017cited by this paper
• Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.

  2017cited by this paper
• Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.

  2017cited by this paper
• Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

  2017cited by this paper
• Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

  2017cited by this paper
• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

  2017cited by this paper
• Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.

  2017cited by this paper
• Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.

  2017cited by this paper
• Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

  2017cited by this paper
• ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellsch

  2017cited by this paper
• Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.

  2017cited by this paper
• Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France

  2017cited by this paper
• High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1‐Positive Metastatic Lung Cancer

  2017cited by this paper
• The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology.

  2016cited by this paper
• Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

  2016cited by this paper
• Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.

  2016cited by this paper
• EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer

  2016cited by this paper
• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

  2016cited by this paper
• Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

  2016cited by this paper
• Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

  2016cited by this paper
• Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

  2016cited by this paper
• A Phase 2 Single Arm Trial of Cabozantinib in Patients with Advanced RET-Rearranged Lung Cancers

  2016cited by this paper
• ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm

  2016cited by this paper
• MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis

  2016cited by this paper
• Executive summary of the SEPAR recommendations for the diagnosis and treatment of non-small cell lung cancer.

  2016cited by this paper
• Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification.

  2016cited by this paper
• Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.

  2016cited by this paper
• Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology

  2016cited by this paper
• Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

  2016cited by this paper
• Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

  2016cited by this paper
• Reliability Assurance of Detection of EML4‐ALK Rearrangement in Non–Small Cell Lung Cancer: The Results of Proficiency Testing in China

  2016cited by this paper
• ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

  2016cited by this paper
• Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

  2016cited by this paper
• MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

  2016cited by this paper
• Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

  2016cited by this paper
• HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers

  2016cited by this paper
• Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease

  2016cited by this paper
• ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma

  2016cited by this paper
• Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

  2016cited by this paper
• Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials

  2015cited by this paper
• MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.

  2015cited by this paper
• SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Intact or Broken-apart RNA: An Alternative Concept for ALK Fusion Screening in Non–Small Cell Lung Cancer (NSCLC)

  2015cited by this paper
• Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

  2015cited by this paper
• Biological Marker Analysis as Part of the CIBERES-RTIC Cancer-SEPAR Strategic Project on Lung Cancer.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

  2015cited by this paper
• Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

  2015cited by this paper
• Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

  2015cited by this paper
• Clinicopathological Characteristics of Patients with Non-Small-Cell Lung Cancer Who Harbor EML4-ALK Fusion Gene: A Meta-Analysis

  2015cited by this paper
• Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

  2015cited by this paper
• EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.

  2015cited by this paper
• HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.

  2015cited by this paper
• A Novel, Highly Sensitive ALK Antibody 1A4 Facilitates Effective Screening for ALK Rearrangements in Lung Adenocarcinomas by Standard Immunohistochemistry

  2015cited by this paper
• Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer

  2015cited by this paper
• Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.

  2015cited by this paper
• Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.

  2015cited by this paper
• Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.

  2015cited by this paper
• ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.

  2015cited by this paper
• Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.

  2015cited by this paper
• Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma

  2015cited by this paper
• ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability

  2015cited by this paper
• Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

  2015cited by this paper
• Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

  2015cited by this paper
• Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

  2015cited by this paper
• Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

  2015cited by this paper
• Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

  2015cited by this paper
• Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

  2015cited by this paper
• The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.

  2015cited by this paper
• MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation

  2015cited by this paper
• Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer

  2015cited by this paper
• The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panels

  2015cited by this paper
• Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma

  2015cited by this paper
• Validation of new cancer biomarkers: a position statement from the European group on tumor markers.

  2015cited by this paper
• Epidermal Growth Factor Receptor–Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options

  2015cited by this paper
• Detection of ROS1 Gene Rearrangement in Lung Adenocarcinoma: Comparison of IHC, FISH and Real-Time RT-PCR

  2015cited by this paper
• Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

  2015cited by this paper
• Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

  2015cited by this paper
• Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients

  2015cited by this paper
• Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification

  2015cited by this paper
• Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor

  2015cited by this paper
• French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas

  2015cited by this paper
• Clinical Implications of Variant ALK FISH Rearrangement Patterns

  2015cited by this paper
• Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.

  2015cited by this paper
• Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer

  2014cited by this paper
• Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay

  2014cited by this paper
• Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group

  2014cited by this paper
• Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

  2014cited by this paper
• Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer

  2014cited by this paper
• Anchored multiplex PCR for targeted next-generation sequencing

  2014cited by this paper
• MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation

  2014cited by this paper
• HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.

  2014cited by this paper
• Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures

  2014cited by this paper
• Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.

  2014cited by this paper

• The progress of biomarkers detection to lung cancer.

  2026cites this paper
• State of the art of perioperative assessment in early non-small-cell lung cancer in Poland in the emerging era of perioperative protocols

  2026cites this paper
• Biomarker Testing Practices for Non-small Cell Lung Cancer: Survey Insights from South Korean Pathology Laboratories.

  2026cites this paper
• Evaluating the Relationship Between Programmed Death Ligand-1 (Clone: 22C3), Anaplastic Lymphoma Kinase (D5F3), and C-ros Oncogene 1 (OT11A1) Expression in Lung Adenocarcinoma

  2026cites this paper
• Breaking resistance barriers: ensartinib as a milestone in anaplastic lymphoma kinase-driven non-small cell lung cancer therapy.

  2026cites this paper
• An allele-specific quantitative PCR strategy for detection of EGFR T790M mutations by liquid biopsy in non-small cell lung cancer patients.

  2025cites this paper
• The updated network meta-analysis of the therapeutic efficacies of lung cancer: A systematic review and meta-analysis

  2025cites this paper
• Diagnosing Malignant Epithelial Neoplasms of the Lung in Cytological Specimens: Cytomorphology, Ancillary Studies and Management

  2025cites this paper
• Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey.

  2025cites this paper
• Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX

  2025cites this paper
• Expert recommendations for biomarker evaluation of advanced non-small cell lung cancer in Thailand

  2025cites this paper
• An Updated Review of the Anticancer Mechanisms and Therapeutic Potential of Naringenin

  2025cites this paper
• Mediastinal restaging in non-small cell lung cancer: comparing endobronchial ultrasound-guided transbronchial needle aspiration and mediastinal cryobiopsy following neoadjuvant therapy

  2025cites this paper
• The Genomic Landscape of Romanian Non-Small Cell Lung Cancer Patients: The Insights from Routine NGS Testing with the OncomineTM Dx Express Test at the PATHOS Molecular Pathology Laboratory

  2025cites this paper
• Emerging biomarkers for early detection of lung cancer

  2025influential citation
• Prevailing challenges in companion diagnostic test development for lung cancer

  2025cites this paper
• Detecting actionable mutations from matched plasma-based versus tissue next-generation sequencing in advanced non-small cell lung cancer: a retrospective single centre analysis on site

  2025cites this paper
• Genetic Alteration Profiling in North Macedonian Lung Cancer Patients

  2025cites this paper
• Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review

  2025cites this paper
• Real world outcomes with Tepotinib in a series of Indian patients with MET exon 14 skipping positive non-small cell lung cancer

  2025cites this paper
• Spectrum of rare EGFR mutations in Indonesian lung adenocarcinoma: Findings from an 8-year analysis of 4,778 cases highlighting the need for advanced targeted therapies

  2025cites this paper
• Validation of ancillary procedures on formalin liquid fixed aspiration cytologic samples: from minimum to maximum

  2025cites this paper
• Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer

  2025cites this paper
• The association between core number and complications in ultrasound-guided percutaneous lung core needle biopsy for subpleural primary lung cancer: a retrospective study

  2025cites this paper
• Anticancer Molecular Mechanisms of Epigallocatechin Gallate: An Updated Review on Clinical Trials

  2025cites this paper
• Comparative analysis of EGFR mutations in circulating tumor DNA and primary tumor tissues from lung cancer patients using BEAMing PCR

  2025cites this paper
• Real-World Data on Osimertinib-Associated Cardiac Toxicity

  2025cites this paper
• EGFR mutation testing across the osimertinib clinical program.

  2025cites this paper
• Characteristics and Associated Survival of Patients Diagnosed With Non–Small Cell Lung Cancer in a Designated Lung Cancer Program in Western Kenya

  2025cites this paper
• Expert Consensus on Diagnosis and Molecular Testing Strategies for Non-Small-Cell Lung Cancer in India

  2025cites this paper
• Optimizing cytology and small biopsy specimen processing for ancillary studies: recommendations from the American Society of Cytopathology taskforce.

  2025cites this paper
• Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

  2025cites this paper
• Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection

  2025cites this paper
• Visceral crisis in a patient with non-small cell lung cancer and ROS1::SDC4 fusion: intrinsic resistance to entrectinib via L2026M mutation—a case report

  2025cites this paper
• Enhanced Detection of Druggable Mutations in Non–Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor Tissue

  2025cites this paper
• Eugenol: An Insight Into the Anticancer Perspective and Pharmacological Aspects

  2025cites this paper
• Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives

  2025cites this paper
• Epidemiological, pathological, and molecular characteristics of lung cancer in Casablanca, Morocco: a retrospective study

  2025cites this paper
• Strategies for improving biomarker testing rates in non-small cell lung cancer in north America: a scoping review

  2025cites this paper
• MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer

  2025cites this paper
• CT-based nomogram for predicting EGFR mutation status in ground-glass nodules of lung adenocarcinoma

  2025cites this paper
• Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye

  2025cites this paper
• Evaluation of turnaround times and performance of in-house ChromaCode high-definition PCR compared to send-out next-generation sequencing in non-small cell lung cancer.

  2025cites this paper
• Achieving equitable, timely and comprehensive biomarker testing for patients with NSCLC.

  2025cites this paper
• Cost-effectiveness Analysis of Comprehensive Genomic Profiling in Patients with Advanced Non-small Cell Lung Cancer Using Real-world Data.

  2025cites this paper
• The Evolving Role of Adjuvant TKI in Lung Cancer: From Historical Trials to Future Strategies National Cancer Center Hospital East, Japan.

  2025cites this paper
• Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials.

  2025cites this paper
• Portable duplex digital PCR for on-site detection of IDH mutations in gliomas.

  2025cites this paper
• Implementing a PREcision meDICine Thoracic (PREDICT) service using in-house reflex testing in a large academic-community practice.

  2025cites this paper
• Molecular Therapy and Targeted Treatment for Cancer (with Surgical Lenses).

  2025cites this paper
• Gene mutation in diabetic patients with lung adenocarcinoma: a real-world retrospective cohort study

  2025cites this paper
• The predictive value of sarcopenia and PET imaging metrics in metastatic non-squamous NSCLC.

  2025cites this paper
• Same‐day molecular testing for targetable mutations in solid tumor cytopathology—The next frontier of the rapid on‐site evaluation

  2025cites this paper
• Biomarker testing in lung cancer: from bench to bedside

  2025cites this paper
• Molecular testing of lung cancer in Australia: consensus best practice recommendations from the Royal College of Pathologists of Australasia in collaboration with the Thoracic Oncology Group of Australasia.

  2025cites this paper
• Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey.

  2025cites this paper
• Prediksi aktivitas Piper retrofractum Vahl terhadap reseptor EGFR yang berkontribusi terhadap kanker paru paru menggunakan docking

  2025cites this paper
• Optimizing Lung Cancer Diagnostics: Insights from a Fast-Track Program in a Complex Healthcare Setting

  2025influential citation
• Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review

  2025cites this paper
• Compassionate Access to Brigatinib for Patients with Non-small-cell Lung Cancer Harboring a ROS1 Rearrangement: Results from the BRIGAROS Study

  2025cites this paper
• Real-World Performance of the EasyPGX® Ready Epidermal Growth Factor Receptor Assay for Genomic Testing of Non-Small Cell Lung Cancer Samples

  2025cites this paper
• RE: Racial and socioeconomic disparities in non-small cell lung cancer molecular diagnostics uptake.

  2025cites this paper
• Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study.

  2025cites this paper
• Comprehensive Genomic Profiling of Indian Patients With Lung Cancer

  2025cites this paper
• Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.

  2024cites this paper
• Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience

  2024cites this paper
• Liquid biopsy for monitoring minimal residual disease in localized and locally-advanced non-small cell lung cancer after radical-intent treatment

  2024cites this paper
• Does caring for patients with advanced non-small cell lung cancer affect health-related quality of life of caregivers? A multicenter, cross-sectional study

  2024cites this paper
• Immunohistochemistry of Lung Cancer Biomarkers

  2024cites this paper
• A rapid turnaround time workflow for a cytological liquid biopsy assay using FNA supernatant specimens

  2024cites this paper
• RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy.

  2024cites this paper
• Real-World Survival Outcomes in Non–Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country

  2024cites this paper
• An introduction to anatomical pathology.

  2024cites this paper
• Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC

  2024cites this paper
• How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer.

  2024cites this paper
• Prognostic Indicators for Precision Treatment of Non-Small Cell Lung Carcinoma

  2024cites this paper
• Immunotherapy for lung cancer.

  2024cites this paper
• Deep learning-based prediction of nodal metastasis in lung cancer using endobronchial ultrasound

  2024cites this paper
• Polypoid lump on the ventral tongue in a pediatric patient with discordant FISH and immunohistochemical studies.

  2024cites this paper
• Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review

  2024cites this paper
• Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing

  2024cites this paper
• Uncovering the link between human endogenous retroviruses, inflammatory pathways, and gastric cancer development

  2024cites this paper
• Resectable Non-Small Cell Lung Cancer Heterogeneity and Recurrence Assessed by Tissue Next-Generation Sequencing Genotyping and Circulating Tumor Cell EZH2 Characterization.

  2024cites this paper
• Intratumoral heterogeneity of oncogenic drivers in mixed histology lung adenocarcinomas: How tissue selection impacts molecular testing?

  2024cites this paper
• Healthcare provider practices and perceptions of biomarker testing in U.S. Veterans with non-small cell lung cancer.

  2024cites this paper
• Repeat Next-Generation Sequencing (15-Gene Panel) in Unifocal, Synchronous, and Metachronous Non-Small-Cell Lung Cancer—A Single-Center Experience

  2024cites this paper
• Biomarker Testing for Guiding Precision Medicine for Patients with Non-Small Cell Lung Cancer.

  2024cites this paper
• Additional reporting of diffuse and homogeneous ROS-1 SP384 immunoreactivity enhances prediction of ROS1 fusion-positive non-small cell lung cancer.

  2024cites this paper
• Rapid on‐site evaluation of fine‐needle aspiration specimens using cytotechnologist‐performed telecytology: Insights and advantages

  2024cites this paper
• Effect on Non-Small Cell Lung Cancer after Combination of Driver Gene Mutations and Anti-PD−1/PD-L1 Immunotherapy as Well as Chemotherapy

  2024cites this paper
• Clinical Utility of Circulating Tumor DNA for Detecting Lung Cancer Mutations by Targeted Next‐Generation Sequencing With Insufficient Tumor Samples

  2024cites this paper
• ASPYRE-Lung: validation of a simple, fast, robust and novel method for multi-variant genomic analysis of actionable NSCLC variants in FFPE tissue

  2024cites this paper
• The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non–small cell lung cancer

  2024cites this paper
• The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non–small cell lung cancer

  2024cites this paper
• Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients

  2024cites this paper
• The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer

  2024cites this paper
• The relevance of the reference range for EGFR testing in non-small cell lung cancer patients.

  2024cites this paper
• A Rare Case of Inflammatory Myofibroblastic Tumor Mimicking Fibrous Adhesions Resulting in Bowel Obstruction

  2024cites this paper
• Real-World Study on Implementation of Genomic Tests for Advanced Lung Adenocarcinoma in Brazil

  2024cites this paper
• Longitudinal Analyses of Circulating-Tumor DNA for Detection of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Progression During Treatment: Data From FLAURA and AURA3.

  2024cites this paper